Laekna (HKSE:02105) Beta: 1.3363 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02105 Laekna Inc HKSE:02105
30 GF Score
Price HK$6.05
! 2 Warning Signs
View Full Analysis

What is Laekna Beta?

Laekna HKSE:02105 -6.27% 30 Beta is 1.3363 as of Aug. 21, 2026. GuruFocus rates HKSE:02105 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-08-21), Laekna's Beta is 1.3363.


Laekna  (HKSE:02105) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Laekna Beta Related Terms


Laekna Beta Historical Data

* Premium members only.

The historical data trend for Laekna's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laekna Beta Chart

Laekna Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Beta
0.00 0.00 0.00 0.00 0.00

Laekna Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

HKSE:02105 vs VRTX, REGN, RVMD: Beta Comparison

For the Biotechnology subindustry, Laekna's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laekna Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Laekna's Beta distribution charts can be found below:

* The bar in red indicates where Laekna's Beta falls into.


HKSE:02105
30GF Score
Laekna Inc HKSE:02105
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laekna Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.3363 mean?
Laekna (HKSE:02105) has a Beta of 1.3363 as of Aug. 21, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Laekna and its competitors.
Is Laekna's Beta too high?
Laekna's current Beta is 1.3363. Overall, Laekna has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Laekna's Beta compare to VRTX and REGN?
Laekna's Beta of 1.3363 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Laekna and its competitors. Laekna's current Beta is 1.3363. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laekna stock overvalued right now?
Laekna (HKSE:02105) has a current Beta of 1.3363. The current Beta is 1.3363. Laekna's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Laekna (HKSE:02105), the current Beta is 1.3363 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Laekna Business Description

Other Exchanges 4U4:Germany
Address No. 3-2-467, 5 Xingbin Road (Lin Li Center, Sino-Italy Ningbo Ecological Park, Zhejiang Province, Yuyao, CHN, 201203
Laekna Inc is a science-driven, clinical-stage biotechnology company. The company has established a comprehensive R&D infrastructure to accelerate the development of molecules from discovery to registrational trials. It has initiated seven clinical trials for LAE102, LAE103, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers. Laekna has two Core Products and other pipeline product candidates. Core Product LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer.
30GF Score

Get the complete analysis for HKSE:02105

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.05
Price